Academic literature on the topic 'H3N2 virus'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'H3N2 virus.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "H3N2 virus"
1
Haredy, Ahmad M., Hiroshi Yamada, Yoshihiro Sakoda, Masatoshi Okamatsu, Naoki Yamamoto, Takeshi Omasa, Yasuko Mori, et al. "Neuraminidase gene homology contributes to the protective activity of influenza vaccines prepared from the influenza virus library." Journal of General Virology 95, no. 11 (November 1, 2014): 2365–71. http://dx.doi.org/10.1099/vir.0.067488-0.
Full textAbstract:
Whole-virus (WV) vaccines from influenza A/duck/Hokkaido/77 (H3N2), and its reassortant strains H3N4, H3N5 and H3N7, which have the same haemagglutinin (HA) gene but different neuraminidase (NA) genes, were prepared from our influenza virus library. Mice were intranasally immunized with equivalent doses of each vaccine (1–0.01 µg per mouse). All of the mice that received the highest dose of each vaccine (1 µg per mouse) showed equivalent high HA-inhibiting (HI) antibody titres and survived the H3N2 challenge viruses. However, mice that received lower doses of vaccine (0.1 or 0.01 µg per mouse) containing a heterologous NA had lower survival rates than those given the H3N2-based vaccine. The lungs of mice challenged with H3N2 virus showed a significantly higher virus clearance rate when the vaccine contained the homologous NA (N2) versus a heterologous NA, suggesting that NA contributed to the protection, especially when the HI antibody level was low. These results suggested that, even if vaccines prepared for a possible upcoming pandemic do not induce sufficient HI antibodies, WV vaccines can still be effective through other matched proteins such as NA.
2
Song, Daesub, Hyoung-Joon Moon, Dong-Jun An, Hye-Young Jeoung, Hyekwon Kim, Min-Joo Yeom, Minki Hong, et al. "A novel reassortant canine H3N1 influenza virus between pandemic H1N1 and canine H3N2 influenza viruses in Korea." Journal of General Virology 93, no. 3 (March 1, 2012): 551–54. http://dx.doi.org/10.1099/vir.0.037739-0.
Full textAbstract:
During recent canine influenza surveillance in South Korea, a novel H3N1 canine influenza virus (CIV) that is a putative reassortant between pandemic H1N1 2009 and H3N2 CIVs was isolated. Genetic analysis of eight genes of the influenza virus revealed that the novel H3N1 isolate presented high similarities (99.1–99.9 %) to pandemic influenza H1N1, except for in the haemagglutinin (HA) gene. The HA gene nucleotide sequence of the novel CIV H3N1 was similar (99.6 %) to that of CIV H3N2 isolated in Korea and China. Dogs infected with the novel H3N1 CIV did not show any notable symptoms, in contrast to dogs infected with H3N2 CIV. Despite no visible clinical signs of disease, nasal shedding of virus was detected and the infected dogs presented mild histopathological changes.
3
Ma, Wenjun, Marie Gramer, Kurt Rossow, and Kyoung-Jin Yoon. "Isolation and Genetic Characterization of New Reassortant H3N1 Swine Influenza Virus from Pigs in the Midwestern United States." Journal of Virology 80, no. 10 (May 15, 2006): 5092–96. http://dx.doi.org/10.1128/jvi.80.10.5092-5096.2006.
Full textAbstract:
ABSTRACT Since the introduction of H3N2 swine influenza viruses (SIVs) into U.S. swine in 1998, H1N2 and H1N1 reassortant viruses have emerged from reassortment between classical H1N1 and H3N2 viruses. In 2004, a new reassortant H3N1 virus (A/Swine/Minnesota/00395/2004) was identified from coughing pigs. Phylogenetic analyses revealed a hemagglutinin segment similar to those of contemporary cluster III H3N2 SIVs and a neuraminidase sequence of contemporary H1N1 origin. The internal genes were of swine, human, and avian influenza virus origin, similar to those of contemporary U.S. cluster III H3N2 SIVs. The recovery of H3N1 is further evidence of reassortment among SIVs and justifies continuous surveillance.
4
Kwasnik, Malgorzata, Marcin Smreczak, Jerzy Rola, Kinga Urbaniak, and Wojciech Rozek. "Serologic investigation of influenza A virus infection in dogs in Poland." Journal of Veterinary Diagnostic Investigation 32, no. 3 (March 24, 2020): 420–22. http://dx.doi.org/10.1177/1040638720913526.
Full textAbstract:
The 2 predominant circulating subtypes of influenza A virus in the dog population, equine-origin H3N8 and avian-origin H3N2, constitute a potential zoonotic risk. We determined the prevalence of influenza A antibodies in 496 dogs in Poland and found 2.21% of sera positive by commercial ELISA. Hemagglutination inhibition (HI) assays indicated 7.25% of sera positive using equine H3N8, swine H3N2, and pandemic H1N1 antigens, with the most frequently detected immune response being to H3N2. Considering interspecies transfer, reassortment ability, and close contact between dogs and humans, infections of dogs with influenza A virus should be monitored.
5
Johansson, B. E., T. M. Moran, C. A. Bona, S. W. Popple, and E. D. Kilbourne. "Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. II. Sequential infection of mice simulates human experience." Journal of Immunology 139, no. 6 (September 15, 1987): 2010–14. http://dx.doi.org/10.4049/jimmunol.139.6.2010.
Full textAbstract:
Abstract In man, vaccination with neuraminidase (NA) in H7N2 virus hybrids elicits greater anti-NA response than does N2 NA in H3N2 conventional vaccine, presumably because humans are H3 hemagglutinin (HA) primed and anti-H3 anamnestic response depresses concomitant N2 responses by antigenic competition. In a laboratory model, BALB/c mice were primed by different schedules of infection with H3N1, H3N2, and H3N7 viruses and given H3N2 and H7N2 vaccines equivalent in NA immunogenicity. In schedules using sequential infections, but not after a single infection with any virus, anti-N2 booster response was fourfold greater with H7N2 vaccine and was reciprocal to the magnitude of anti-H3 response. Thus, HA-influenced suppression of immunologic response to viral NA requires adequate HA priming but is not unique to man and can be studied in the murine model. An incidental finding of this study was the sharing of cross-reactive determinants by N1, N2, and N7 NA.
6
Nelson, Martha I., Amy L. Vincent, Pravina Kitikoon, Edward C. Holmes, and Marie R. Gramer. "Evolution of Novel Reassortant A/H3N2 Influenza Viruses in North American Swine and Humans, 2009–2011." Journal of Virology 86, no. 16 (June 13, 2012): 8872–78. http://dx.doi.org/10.1128/jvi.00259-12.
Full textAbstract:
Novel H3N2 influenza viruses (H3N2v) containing seven genome segments from swine lineage triple-reassortant H3N2 viruses and a 2009 pandemic H1N1 (H1N1pdm09) matrix protein segment (pM) were isolated from 12 humans in the United States between August and December 2011. To understand the evolution of these novel H3N2 viruses in swine and humans, we undertook a phylogenetic analysis of 674 M sequences and 388 HA and NA sequences from influenza viruses isolated from North American swine during 2009–2011, as well as HA, NA, and M sequences from eight H3N2v viruses isolated from humans. We identified 34 swine influenza viruses (termed rH3N2p) with the same combination of H3, N2, and pM segments as the H3N2v viruses isolated from humans. Notably, these rH3N2p viruses were generated in swine via reassortment events between H3N2 viruses and the pM segment approximately 4 to 10 times since 2009. The pM segment has also reassorted with multiple distinct lineages of H1 virus, especially H1δ viruses. Importantly, the N2 segment of all H3N2v viruses isolated from humans is derived from a genetically distinct N2 lineage that has circulated in swine since being acquired by reassortment with seasonal human H3N2 viruses in 2001–2002, rather than from the N2 that is associated with the 1998 H3N2 swine lineage. The identification of this N2 variant may have implications for influenza vaccine design and the potential pandemic threat of H3N2v to human age groups with differing levels of prior exposure and immunity.
7
Rajão, Daniela S., Phillip C. Gauger, Tavis K. Anderson, Nicola S. Lewis, Eugenio J. Abente, Mary Lea Killian, Daniel R. Perez, Troy C. Sutton, Jianqiang Zhang, and Amy L. Vincent. "Novel Reassortant Human-Like H3N2 and H3N1 Influenza A Viruses Detected in Pigs Are Virulent and Antigenically Distinct from Swine Viruses Endemic to the United States." Journal of Virology 89, no. 22 (August 26, 2015): 11213–22. http://dx.doi.org/10.1128/jvi.01675-15.
Full textAbstract:
ABSTRACTHuman-like swine H3 influenza A viruses (IAV) were detected by the USDA surveillance system. We characterized two novel swine human-like H3N2 and H3N1 viruses with hemagglutinin (HA) genes similar to those in human seasonal H3 strains and internal genes closely related to those of 2009 H1N1 pandemic viruses. The H3N2 neuraminidase (NA) was of the contemporary human N2 lineage, while the H3N1 NA was of the classical swine N1 lineage. Both viruses were antigenically distant from swine H3 viruses that circulate in the United States and from swine vaccine strains and also showed antigenic drift from human seasonal H3N2 viruses. Their pathogenicity and transmission in pigs were compared to those of a human H3N2 virus with a common HA ancestry. Both swine human-like H3 viruses efficiently infected pigs and were transmitted to indirect contacts, whereas the human H3N2 virus did so much less efficiently. To evaluate the role of genes from the swine isolates in their pathogenesis, reverse genetics-generated reassortants between the swine human-like H3N1 virus and the seasonal human H3N2 virus were tested in pigs. The contribution of the gene segments to virulence was complex, with the swine HA and internal genes showing effectsin vivo. The experimental infections indicate that these novel H3 viruses are virulent and can sustain onward transmission in pigs, and the naturally occurring mutations in the HA were associated with antigenic divergence from H3 IAV from humans and swine. Consequently, these viruses could have a significant impact on the swine industry if they were to cause more widespread outbreaks, and the potential risk of these emerging swine IAV to humans should be considered.IMPORTANCEPigs are important hosts in the evolution of influenza A viruses (IAV). Human-to-swine transmissions of IAV have resulted in the circulation of reassortant viruses containing human-origin genes in pigs, greatly contributing to the diversity of IAV in swine worldwide. New human-like H3N2 and H3N1 viruses that contain a mix of human and swine gene segments were recently detected by the USDA surveillance system. The human-like viruses efficiently infected pigs and resulted in onward airborne transmission, likely due to the multiple changes identified between human and swine H3 viruses. The human-like swine viruses are distinct from contemporary U.S. H3 swine viruses and from the strains used in swine vaccines, which could have a significant impact on the swine industry due to a lack of population immunity. Additionally, public health experts should consider an appropriate assessment of the risk of these emerging swine H3 viruses for the human population.
8
Ma, Jingjiao, Huigang Shen, Qinfang Liu, Bhupinder Bawa, Wenbao Qi, Michael Duff, Yuekun Lang, et al. "Pathogenicity and Transmissibility of Novel Reassortant H3N2 Influenza Viruses with 2009 Pandemic H1N1 Genes in Pigs." Journal of Virology 89, no. 5 (December 24, 2014): 2831–41. http://dx.doi.org/10.1128/jvi.03355-14.
Full textAbstract:
ABSTRACTAt least 10 different genotypes of novel reassortant H3N2 influenza viruses with 2009 pandemic H1N1 [A(H1N1)pdm09] gene(s) have been identified in U.S. pigs, including the H3N2 variant with a single A(H1N1)pdm09 M gene, which has infected more than 300 people. To date, only three genotypes of these viruses have been evaluated in animal models, and the pathogenicity and transmissibility of the other seven genotype viruses remain unknown. Here, we show that three H3N2 reassortant viruses that contain 3 (NP, M, and NS) or 5 (PA, PB2, NP, M, and NS) genes from A(H1N1)pdm09 were pathogenic in pigs, similar to the endemic H3N2 swine virus. However, the reassortant H3N2 virus with 3 A(H1N1)pdm09 genes and a recent human influenza virus N2 gene was transmitted most efficiently among pigs, whereas the reassortant H3N2 virus with 5 A(H1N1)pdm09 genes was transmitted less efficiently than the endemic H3N2 virus. Interestingly, the polymerase complex of reassortant H3N2 virus with 5 A(H1N1)pdm09 genes showed significantly higher polymerase activity than those of endemic and reassortant H3N2 viruses with 3 A(H1N1)pdm09 genes. Further studies showed that an avian-like glycine at position 228 at the hemagglutinin (HA) receptor binding site is responsible for inefficient transmission of the reassortant H3N2 virus with 5 A(H1N1)pdm09 genes. Taken together, our results provide insights into the pathogenicity and transmissibility of novel reassortant H3N2 viruses in pigs and suggest that a mammalian-like serine at position 228 in the HA is critical for the transmissibility of these reassortant H3N2 viruses.IMPORTANCESwine influenza is a highly contagious zoonotic disease that threatens animal and public health. Introduction of 2009 pandemic H1N1 virus [A(H1N1)pdm09] into swine herds has resulted in novel reassortant influenza viruses in swine, including H3N2 and H1N2 variants that have caused human infections in the United States. We showed that reassortant H3N2 influenza viruses with 3 or 5 genes from A(H1N1)pdm09 isolated from diseased pigs are pathogenic and transmissible in pigs, but the reassortant H3N2 virus with 5 A(H1N1)pdm09 genes displayed less efficient transmissibility than the endemic and reassortant H3N2 viruses with 3 A(H1N1)pdm09 genes. Further studies revealed that an avian-like glycine at the HA 228 receptor binding site of the reassortant H3N2 virus with 5 A(H1N1)pdm09 genes is responsible for less efficient transmissibility in pigs. Our results provide insights into viral pathogenesis and the transmission of novel reassortant H3N2 viruses that are circulating in U.S. swine herds and warrant future surveillance.
9
Mancini, Dalva Assunção Portari, Rita Maria Zucatelli Mendonça, Aparecida Santo Pietro Pereira, Adélia Hiroko Nagamori Kawamoto, Camila Infantosi Vannucchi, José Ricardo Pinto, Enio Mori, and Jorge Mancini Filho. "Influenza viruses in adult dogs raised in rural and urban areas in the state of São Paulo, Brazil." Revista do Instituto de Medicina Tropical de São Paulo 54, no. 6 (December 2012): 311–14. http://dx.doi.org/10.1590/s0036-46652012000600004.
Full textAbstract:
In 1970, searching for the interspecies transmission of influenza viruses led to the first study on influenza viruses in domestic animals. Birds and mammals, including human beings, are their natural hosts; however, other animals may also play a role in the virus epidemiology. The objective was to investigate the incidence of influenza viruses in adult dogs raised in rural (9, 19.56%) and urban (37, 80.43%) areas in the state of São Paulo, Brazil. Dog serum samples were examined for antibodies to influenza viruses by the hemagglutination inhibition (HI) test using the corresponding antigens from the circulating viruses in Brazil. Dogs from rural areas presented antibodies to influenza A H3N2, and influenza A H7N7 and H3N8. In rural areas, dog sera displayed mean titers as 94.37, 227.88, 168.14, 189.62 HIU/25 µL for subtypes H1N1, H3N2, H7N7, H3N8, respectively. About 84% and 92% of dogs from urban areas exhibited antibodies to human influenza A H1N1 and H3N2, respectively, with statistical difference at p < 0.05 between the mean titers of antibodies to H1N1 and H3N2. About 92% and 100% were positive for H7N7 and H3N8, respectively. In dogs from urban areas, the mean titers of antibodies against influenza A H1N1, H3N2, H7N7 and H3N8, were 213.96, 179.42, 231.76, 231.35 HIU/25 µL respectively. The difference among them was not statistically significant at p > 0.05. In conclusion, these dogs were positive for both human and equine influenza viruses. The present study suggests the first evidence that influenza viruses circulate among dogs in Brazil.
10
MOON, H., M. HONG, J. K. KIM, B. SEON, W. NA, S. J. PARK, D. J. AN, et al. "H3N2 canine influenza virus with the matrix gene from the pandemic A/H1N1 virus: infection dynamics in dogs and ferrets." Epidemiology and Infection 143, no. 4 (June 30, 2014): 772–80. http://dx.doi.org/10.1017/s0950268814001617.
Full textAbstract:
SUMMARYAfter an outbreak of pandemic influenza A/H1N1 (pH1N1) virus, we had previously reported the emergence of a recombinant canine influenza virus (CIV) between the pH1N1 virus and the classic H3N2 CIV. Our ongoing routine surveillance isolated another reassortant H3N2 CIV carrying the matrix gene of the pH1N1 virus from 2012. The infection dynamics of this H3N2 CIV variant (CIV/H3N2mv) were investigated in dogs and ferrets via experimental infection and transmission. The CIV/H3N2mv-infected dogs and ferrets produced typical symptoms of respiratory disease, virus shedding, seroconversion, and direct-contact transmissions. Although indirect exposure was not presented for ferrets, CIV/H3N2mv presented higher viral replication in MDCK cells and more efficient transmission was observed in ferrets compared to classic CIV H3N2. This study demonstrates the effect of reassortment of the M gene of pH1N1 in CIV H3N2.
Dissertations / Theses on the topic "H3N2 virus"
1
Plante, Martin. "Réponse immunitaire du porc face au virus influenza et amélioration des vaccins disponibles pour combattre ce virus." Mémoire, Université de Sherbrooke, 1996. http://savoirs.usherbrooke.ca/handle/11143/4341.
Full textAbstract:
L'objectif de cette étude était double. Il s'agissait dans un premier temps de caractériser l'immunosuppression produite chez des porcs infectés par une souche de virus influenza H3N2. La deuxième partie de cette étude consistait à tester le potentiel adjuvant d'un dérivé de mannose (l'Acemannan) aux propriétés immunostimulantes. Lors de la première partie de cette étude, les effets d'une infection par le virus influenza furent évalués chez le porc. Il fut démontré par différents essais que la prolifération mitogène-dépendante ainsi que la sous-population de lymphocytes T auxilliaires sont affectées de façon négative lors de ce type d'infection. L'activité des cellules N. K est grandement influencée par le stress des animaux. Dans la deuxième partie de cette étude, les effets de l'Acemannan furent déterminés sur la réponse immunitaire du porc en réponse à un vaccin anti-virus influenza. Ceci a été effectué dans le but de vérifier le potentiel de l'Acemannan comme adjuvant couplé à des vaccins. Ces expériences ont permis de démontrer que l'Acemannan possède des effets activateurs ou inhibiteurs selon le type cellulaire en cause. Des effets activateurs ont été mis en évidence au niveau de la production d'anticorps et de la réponse proliférative des lymphocytes mononucles du sang périphérique du porc (PBML) tandis qu'un effet inhibiteur a été rapporté au niveau de l'activité des cellules N. K. [Résumé abrégé par UMI].
2
Mittelholzer, Camilla Maria. "Influenza virus - protection and adaptation /." Stockholm, 2006. http://diss.kib.ki.se/2006/91-7140-656-5/.
Full text
3
Phillipson, Louisa. "Sialyl oligosaccharide glycopolymers : their synthesis and use as probes of the influenza A H3N2 virus evolution." Thesis, University of Reading, 2005. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.424034.
Full text
4
Medeiros, Rita. "Évolution des glycoprotéines des virus grippaux A (H3N2) récents : étude de leurs interactions avec les acides sialiques." Paris 7, 2002. http://www.theses.fr/2002PA077123.
Full text
5
Bergeron, Corinne. "Composition génétique de semences vaccinales H3N2 et construction d'un virus vecteur : une histoire d'encapsidation de segments chez les virus influenza de type A." Phd thesis, Université Claude Bernard - Lyon I, 2009. http://tel.archives-ouvertes.fr/tel-00625467.
Full textAbstract:
L'empaquetage des huit segments du génome des virus influenza de type A est une des étapes clef du cycle viral. Il intervient également dans l'apparition de virus réassortants, les virus pandémiques par exemple, ce qui en fait un enjeu fondamental de la recherche actuelle.Nous avons étudié ce mécanisme au cours de deux études, la première portant sur les vaccins antigrippaux (réassortiment), la seconde visant à construire un virus vecteur (incorporation d'un segment hétérologue). Les semences vaccinales sont obtenues par co-infection d'oeufs de poule embryonnés avec deux souches virales une donneuse (souche circulante de référence) et une accepteuse (A/Puerto Rico/8/34 (H1N1) (PR8)). L'analyse de la composition génétique de treize semences vaccinales H3N2 montre que le segment PB1 de la souche donneuse est présent dans plus de 50 % des semences analysées et qu'une grande variété de réassortants,allant de 6:2 à 2:6 (PR8:H3N2), peut résulter de ces coinfections. Des expériences de compétition d'encapsidation de segments à l'aide de la génétique inverse révèlent que l'encapsidation sélective du segment PB1 dépend de son environnement génétique notamment l'origine virale des segments HA et NA. La seconde partie de mon travail de thèse a été consacrée à la construction d'un vecteur réplicatif sur la base d'un virus influenza H3 naturel sans segment NA. Aucune des constructions contenant le transgène gfp n'a été incorporée dans les particules virales, contrairement à ce qui a été décrit dans la littérature. Bien que les mécanismes moléculaires régissant l'incorporation des segments des virus influenza A demeurent très complexes, le fond génétique semble être déterminant pour ce processus.
6
Hardy, Isabelle. "Caractérisation antigénique et moléculaire des virus influenza A/H3N2 collectés dans la province de Québec lors des trois dernières saisons grippales, 1997-2000." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 2001. http://www.collectionscanada.ca/obj/s4/f2/dsk3/ftp04/MQ62067.pdf.
Full text
7
Tu, Véronique. "Évaluation in vitro de l'efficacité du peramivir contre des variants du virus de l'influenza A(H1N1), A(H3N2) et B contenant différentes mutations dans le gène de la neuraminidase." Master's thesis, Université Laval, 2017. http://hdl.handle.net/20.500.11794/27820.
Full textAbstract:
Les virus influenza sont des pathogènes respiratoires responsables d’épidémies saisonnières touchant 10 à 20% de la population mondiale chaque année, constituant donc un problème majeur de santé publique. La vaccination annuelle réduit l’impact des épidémies grippales; cependant, un mésappariement entre les souches vaccinales et circulantes peut parfois survenir et résulter en un échec de protection de la population. Dans ces cas, il est important d’avoir un traitement adéquat afin de traiter l’infection virale. Les inhibiteurs de la neuraminidase (INAs) constituent la principale classe d’antiviraux recommandée pour la prévention et le traitement des infections grippales. Les INAs lient de façon compétitive le site actif de la neuraminidase (NA), ce qui bloque la libération des virions des cellules hôtes inhibant de la sorte la dissémination du virus dans le tractus respiratoire. L’émergence sporadique de virus résistants à l’oseltamivir et/ou au zanamivir avec de faibles taux de transmission a été identifiée lors de traitements des souches saisonnières de l’influenza. Le développement de nouveaux antiviraux devient donc un sujet important d’investigation. Le peramivir, un nouvel INA disponible depuis peu en Amérique du Nord, exerce une activité sur des virus influenza A et B et son efficacité contre des mutants résistants à l’oseltamivir ou au zanamivir n’a pas encore été complètement caractérisée. À cause des différences dans la liaison des INAs avec l’enzyme cible, la nature des mutations de résistance peut varier d’un INA à l’autre bien que certaines mutations pourraient engendrer une résistance croisée à plusieurs INAs. Nous avons démontré que le peramivir s’avère très actif contre les différents sous-types de grippe saisonnière, quoique certains variants aient présentés des phénotypes de multi-résistance à l’oseltamivir, au zanamivir ainsi qu’au peramivir. À cet égard, un nouveau mécanisme de résistance d’un variant menant à la résistance croisée aux INAs a été décrit (I427T/Q313R) dans le cadre de ce mémoire et a permis de comprendre comment des substitutions retrouvées hors du site actif de la NA peuvent affecter la capacité de réplication du virus et sa résistance aux antiviraux.Influenza viruses are respiratory pathogens responsible for seasonal epidemics affecting 10 to 20% of the world's population every year, thus constituting a major public health impact. Annual vaccination reduces the impact of influenza epidemics; however, a mismatch between the vaccine strain and the circulating strain can sometimes occur and result in an unsuccessful attempt in protecting the population. In such cases, it is important to have adequate treatment to treat influenza infections. Neuraminidase inhibitors (NAIs) are the primary class of antiviral agents recommended for the prevention and treatment of influenza infections. NAIs competitively bind the neuraminidase (NA) active site, blocking the release of virions from host cells and thereby inhibiting the spread of the virus into the respiratory tract. The sporadic emergence of oseltamivir- and/or zanamivir-resistant viruses with low transmission rates was identified in seasonal influenza strains. The development of new antivirals thus became an important subject of investigation. Peramivir, a new NAI recently available in North America, exerts its activity against influenza A and B viruses, but its effectiveness against mutations conferring resistance to oseltamivir or zanamivir has not yet been fully characterized. Due to differences in the binding of NAIs to the target enzyme, the nature of the resistance mutations may vary from one NAI to another, although some mutations could induce global NAI cross-resistance. We have demonstrated that peramivir is highly active against the different seasonal influenza subtypes, although some variants have shown multi-resistance phenotypes to oseltamivir, zanamivir as well as peramivir. In this regard, a new resistance mechanism by which a NA variant leads to NAI cross-resistance (I427T/Q313R) has been described in this thesis and has helped to understand how substitutions found outside the NA active site can affect the replication kinetics of the virus and its resistance to antivirals.
8
Barthélémy, Adeline. "Rôle des cellules T natural killer invariants (iNKT) dans la surinfection bactérienne post-grippale." Thesis, Lille 2, 2016. http://www.theses.fr/2016LIL2S002/document.
Full textAbstract:
Durant l’infection par le virus Influenza A (IAV), les changements physiques et immunologiques du poumon prédisposent l’hôte aux surinfections bactériennes. Les cellules T Natural Killer invariantes (iNKT) sont des lymphocytes T innés pouvant avoir des rôles bénéfiques ou délétères durant l’infection. Nos objectifs ont visé à (i) étudier le rôle naturel des cellules iNKT et (ii) à rechercher l’effet d’une activation exogène des cellules iNKT dans la surinfection bactérienne post-influenza.Lors de mon arrivée, le laboratoire venait de décrire, pour la première fois en contexte infectieux, que les cellules iNKT étaient capables de produire de l’IL-22 au cours de l’infection grippale. Cette cytokine joue un rôle majeur dans les processus de maintien et de réparation des épithéliums. L’une des causes des surinfections bactériennes post-grippales étant l’altération et/ou la perte de l’intégrité de l’épithélium pulmonaire, nous nous sommes proposés d’étudier le rôle potentiel de cette cytokine dans un modèle expérimental de surinfection bactérienne à S. pneumoniae. Nous avons ainsi pu montrer que si cette cytokine ne joue pas un rôle majeur dans la réponse anti-virale de l’hôte, l’IL-22 participe au contrôle de l’inflammation au cours de l’infection grippale et joue un rôle protecteur dans la surinfection bactérienne.Par ailleurs, l’utilisation de souris dépourvues en cellules iNKT (Jα18-/-) a permis de montrer que les cellules iNKT limitent la susceptibilité aux surinfections et réduisent le synergisme létal de la coinfection virus/bactérie. Au moment de l’infection bactérienne, les cellules iNKT des souris grippées sont incapables de produire de l’IFN-γ, cytokine dont nous avons montré le rôle essentiel dans les mécanismes de défense antibactérienne. Le défaut d’activation des cellules iNKT chez les souris surinfectées est lié à l’interleukine-10 (IL-10), cytokine immunosuppressive induite par l’infection virale, plutôt qu’à un défaut intrinsèque des cellules iNKT. L’IL-10 inhibe l’activation des cellules iNKT en réponse au pneumocoque en inhibant la production d’IL-12 par les cellules dendritiques dérivées de monocytes (MoDCs). La neutralisation de l’IL-10 restaure l’activation des cellules iNKT et augmente la résistance à la surinfection. Ainsi, les cellules iNKT ont un rôle bénéfique (en amont de la colonisation bactérienne) dans le contrôle de la surinfection bactérienne de la grippe et représentent une cible de l’immunosuppression.Nous avons par la suite étudié la possibilité que le superagoniste des cellules iNKT, l’ α-galactosylceramide (α-GalCer) puisse limiter la surinfection bactérienne. Pour cela, les souris ont été traitées par voie intranasale avec de l’α-GalCer à différents temps post-influenza, juste avant l’infection par le pneumocoque. Le traitement à jour 3, au pic de la réplication virale, limite fortement la surinfection. Cependant, l’inoculation d’α-GalCer pendant la phase aiguë du virus (jour 7) ne permet pas d’activer les cellules iNKT pulmonaires et n’a pas d’effet sur la surinfection. L’absence d’activation des cellules iNKT n’est pas intrinsèque et est associée à une disparition complète des cellules dendritiques CD103+ respiratoires (cDCs), lesquelles sont cruciales dans l’activation des cellules iNKTs. À des temps plus tardifs (jour 14), les cDCs repeuplent le poumon et l’α-GalCer promeut l’activité antibactérienne des cellules iNKT.Pris dans son ensemble, cette étude souligne le rôle des cellules iNKT dans la surinfection bactérienne de la grippe et ouvre de nouvelles voies thérapeutiques afin de limiter les surinfections bactériennes post-influenzaXDurant l’infection par le virus Influenza A (IAV), les changements physiques et immunologiques du poumon prédisposent l’hôte aux surinfections bactériennes. Les cellules T Natural Killer invariantes (iNKT) sont des lymphocytes T innés pouvant avoir des rôles bénéfiques ou délétères durant l’infection. Nos objectifs ont visé à (i) étudier le rôle naturel des cellules iNKT et (ii) à rechercher l’effet d’une activation exogène des cellules iNKT dans la surinfection bactérienne post-influenza.Lors de mon arrivée, le laboratoire venait de décrire, pour la première fois en contexte infectieux, que les cellules iNKT étaient capables de produire de l’IL-22 au cours de l’infection grippale. Cette cytokine joue un rôle majeur dans les processus de maintien et de réparation des épithéliums. L’une desDuring the infection by the virus Influenza A ( IAV), the physical and immunological changes of the lung predispose the host to the bacterial secondary infections. The invariant cells(units) T Natural Killer iNKT ) are lymphocytes T innate being able to have beneficial or noxious roles during the infection. Our objectives aimed at i) to study the natural role of cells(units) iNKT and ii) to look for the effect of an exogenous activation of cells(units) iNKT in the bacterial secondary infection post-influenza. During my arrival, the laboratory had just described, for the first time in infectious context, that cells(units) iNKT were capable of producing of IL-22 during the flu-like infection. This cytokine plays a major role in the processes of preservation and repair of epitheliums [...]
9
Oxburgh, Leif. "Studies of the evolution of the haemagglutinin protein of equine influenza virus H3N8 /." Uppsala : Swedish Univ. of Agricultural Sciences (Sveriges lantbruksuniv.), 1998. http://epsilon.slu.se/avh/1998/91-576-5403-4.gif.
Full text
10
Livesay, Georgia Jane. "Field and experimental approaches to the study of of influenza A/equine-2/Suffolk/89 (H3N8) virus : construction and characterisation of vaccina virus recombinants, and their use in immunoassays." Thesis, University of Cambridge, 1994. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.337874.
Full textBooks on the topic "H3N2 virus"
1
Oxburgh, Leif. Studies of the evolution of the haemagglutinin protein of equine influenza virus H3N8. Uppsala: Sveriges Lantbruksuniversitet, 1998.
Find full text
2
Alexander, D. J., N. Phin, and M. Zuckerman. Influenza. Edited by I. H. Brown. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780198570028.003.0037.
Full textAbstract:
Influenza is a highly infectious, acute illness which has affected humans and animals since ancient times. Influenza viruses form the Orthomyxoviridae family and are grouped into types A, B, and C on the basis of the antigenic nature of the internal nucleocapsid or the matrix protein. Infl uenza A viruses infect a large variety of animal species, including humans, pigs, horses, sea mammals, and birds, occasionally producing devastating pandemics in humans, such as in 1918 when it has been estimated that between 50–100 million deaths occurred worldwide.There are two important viral surface glycoproteins, the haemagglutinin (HA) and neuraminidase (NA). The HA binds to sialic acid receptors on the membrane of host cells and is the primary antigen against which a host’s antibody response is targeted. The NA cleaves the sialic acid bond attaching new viral particles to the cell membrane of host cells allowing their release. The NA is also the target of the neuraminidase inhibitor class of antiviral agents that include oseltamivir and zanamivir and newer agents such as peramivir. Both these glycoproteins are important antigens for inducing protective immunity in the host and therefore show the greatest variation.Influenza A viruses are classified into 16 antigenically distinct HA (H1–16) and 9 NA subtypes (N1–9). Although viruses of relatively few subtype combinations have been isolated from mammalian species, all subtypes, in most combinations, have been isolated from birds. Each virus possesses one HA and one NA subtype.Last century, the sudden emergence of antigenically different strains in humans, termed antigenic shift, occurred on three occasions, 1918 (H1N1), 1957 (H2N2) and 1968 (H3N2), resulting in pandemics. The frequent epidemics that occur between the pandemics are as a result of gradual antigenic change in the prevalent virus, termed antigenic drift. Epidemics throughout the world occur in the human population due to infection with influenza A viruses, such as H1N1 and H3N2 subtypes, or with influenza B virus. Phylogenetic studies have led to the suggestion that aquatic birds that show no signs of disease could be the source of many influenza A viruses in other species. The 1918 H1N1 pandemic strain is thought to have arisen as a result of spontaneous mutations within an avian H1N1 virus. However, most pandemic strains, such as the 1957 H2N2, 1968 H3N2 and 2009 pandemic H1N1, are considered to have emerged by genetic re-assortment of the segmented RNA genome of the virus, with the avian and human influenza A viruses infecting the same host.Influenza viruses do not pass readily between humans and birds but transmission between humans and other animals has been demonstrated. This has led to the suggestion that the proposed reassortment of human and avian influenza viruses takes place in an intermediate animal with subsequent infection of the human population. Pigs have been considered the leading contender for the role of intermediary because they may serve as hosts for productive infections of both avian and human viruses, and there is good evidence that they have been involved in interspecies transmission of influenza viruses; particularly the spread of H1N1 viruses to humans. Apart from public health measures related to the rapid identification of cases and isolation. The main control measures for influenza virus infections in human populations involves immunization and antiviral prophylaxis or treatment.
Book chapters on the topic "H3N2 virus"
1
Tan, Zhiying, Beibei Xu, Kenli Li, Taijiao Jiang, and Yousong Peng. "Predicting the Antigenic Variant of Human Influenza A(H3N2) Virus with a Stacked Auto-Encoder Model." In Communications in Computer and Information Science, 302–10. Singapore: Springer Singapore, 2017. http://dx.doi.org/10.1007/978-981-10-6388-6_25.
Full text
2
Camilloni, Barbara, Michela Basileo, Giuseppe Menculini, Paolo Tozzi, and Anna Maria Iorio. "Partial Protection Induced by 2011–2012 Influenza Vaccine Against Serologically Evidenced A(H3N2) Influenza Virus Infections in Elderly Institutionalized People." In Advances in Experimental Medicine and Biology, 45–53. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/5584_2015_5003.
Full text
3
Bednarska, K., E. Hallmann-Szelińska, K. Kondratiuk, and L. B. Brydak. "Antigenic Drift of A/H3N2/Virus and Circulation of Influenza-Like Viruses During the 2014/2015 Influenza Season in Poland." In Advances in Experimental Medicine and Biology, 33–38. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/5584_2016_216.
Full text
4
Shin, Gee Yen. "Vaccination Schedules." In Tutorial Topics in Infection for the Combined Infection Training Programme. Oxford University Press, 2019. http://dx.doi.org/10.1093/oso/9780198801740.003.0062.
Full textAbstract:
The vaccines included in the current UK Immunisation Schedule offer protection against the following pathogens: A. Viruses ● Measles ● Mumps ● Rubella ● Polio ● Human Papilloma Virus (certain serotypes) ● Rotavirus ● Influenza virus (flu A and B) ● Varicella zoster virus (shingles) ● Hepatitis B virus B. Bacteria ● Corynebacterium diphtheriae (Diphtheria) ● Clostridium tetani (Tetanus) ● Bordetella pertussis (Pertussis) ● Haemophilus influenzae type B (Hib) ● Neisseria meningitidis (Meningococcal disease—certain serotypes) ● Streptococcus pneumoniae (Pneumococcal disease—certain serotypes) The UK Immunisation Schedule has evolved over several decades and reflects changes in vaccine development and commercial availability, national and sometimes international disease epidemiology, and the latest expert opinion. It is designed to offer optimal protection against infectious diseases of childhood to infants and children at the most appropriate age. The most up-to-date information about the UK Immunisation Schedule is available on the online version of the Department of Health publication commonly known as the ‘Green Book’: Immunisation Against Infectious Disease Handbook (see Further reading. Various chapters of the online version are updated at regular intervals; thus, it is very important to refer to the online version of the Green Book on the website for current guidance. Changes to the UK Immunisation Schedule are made on the recommendation of the independent Joint Committee on Vaccines and Immunisation (JCVI). Several of the UK Immunisation Schedule vaccines are combined vaccines: ● Measles, mumps, and rubella (MMR). ● Hexavalent diphtheria, tetanus, acellular pertussis, inactivated polio virus, Haemophilus influenza type b, hepatitis B (DTaP/IPV/Hib/HepB). ● Diphtheria, tetanus, acellular pertussis, inactivated polio, and Haemophilus influenzae (DTaP/IPV/Hib). ● Diphtheria, tetanus, acellular pertussis, inactivated polio (DTaP/IPV). ● Tetanus, diphtheria, and inactivated polio (Td/IPV). ● Inactivated influenza vaccine: influenza A H1N1, H3N2, influenza B. ● Live attenuated intranasal influenza vaccine: influenza A H1N1, H3N2, influenza B. In the UK, vaccines against single pathogens covered by the MMR vaccine are not recommended and not available in the National Health Service (NHS). There has been some limited demand for single-target vaccines, e.g. measles, due to misguided and unfounded concerns about the alleged risks of autism following MMR.
5
M., Halima, Ihsana Banu Ishthiaq, Sneha Unnikrishnan, and Karthikeyan Ramalingam. "Nanoemulsion-Based Antiviral Drug Therapy." In Handbook of Research on Nanoemulsion Applications in Agriculture, Food, Health, and Biomedical Sciences, 194–212. IGI Global, 2022. http://dx.doi.org/10.4018/978-1-7998-8378-4.ch009.
Full textAbstract:
Nanoemulsions are an attractive approach for the delivery of antiviral drugs in the treatment of various viral infections. Nanoemulsions are easy to plan and develop, and their components exhibit high variability. Nanoemulsion system and its components have certain biophysical properties which could increase the efficacy of drug therapy. Pulmonary surfactant (PS)-assisted antiviral drug delivery by nanoemulsion system could be another effective approach for the treatment of COVID-19. Antiviral drug delivery of nebulization using an animation system could increase the efficacy of antiviral drug against COVID-19. Ginkgo biloba polyprenol nanoemulsion was also found to be stable, non-toxic, and had strong antiviral activity against influenza A H3N2 and hepatitis B virus in vitro. Nanoemulsion systems possess certain properties that make their system suitable for drug delivery by mobilization and hence would be promising systems for therapeutics in the future.
6
Smallman-Raynor, Matthew, Andrew Cliff, Keith Ord, and Peter Haggett. "Pandemics, I." In A Geography of Infection, 91–110. Oxford University Press, 2022. http://dx.doi.org/10.1093/oso/9780192848390.003.0004.
Full textAbstract:
‘Pandemics, I: Pandemics in History’ surveys the historical geography of pandemic events. Special attention is paid to those diseases that have manifested as worldwide epidemics and to which the term global pandemic is commonly applied, namely plague, cholera, influenza, and the human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS). A synoptic overview of approximately 35 such pandemics since the sixth century AD is presented. Consecutive sections survey the three great plague pandemics of history (Plague of Justinian, Black Death, and the Third Pandemic of the 1850s–1950s); the seven cholera pandemics of the nineteenth to twenty-first centuries (including the ongoing pandemic of El Tor cholera); the 24 influenza pandemics of the modern era (including the H1N1/Spanish, H2N2/Asian, H3N2/Hong Kong, and H1N1/09 ‘swine flu’ pandemics of the twentieth and twenty-first centuries); and the ongoing pandemic of HIV/AIDS that first emerged in the 1980s.
7
Zhang, Ran, Rick Oerlemans, Chao Wang, Lili Zhang, and Matthew R. Groves. "Drug Repurposing Techniques in Viral Diseases." In Drug Repurposing - Molecular Aspects and Therapeutic Applications [Working Title]. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.101443.
Full textAbstract:
Since the advent of the twentieth century, several severe virus outbreaks have occurred—H1N1 (1918), H2N2 (1957), H3N2 (1968), H1N1 (2009) and recently COVID-19 (2019)—all of which have posed serious challenges to public health. Therefore, rapid identification of efficacious antiviral medications is of ongoing paramount importance in combating such outbreaks. Due to the long cycle of drug development, not only in the development of a “safe” medication but also in mandated and extensive (pre)clinical trials before a drug can be safely licensed for use, it is difficult to access effective and safe novel antivirals. This is of particular importance in addressing infectious disease in appropriately short period of time to limit stress to ever more interlinked societal infrastructures; including interruptions to economic activity, supply routes as well as the immediate impact on health care. Screening approved drugs or drug candidates for antiviral activity to address emergent diseases (i.e. repurposing) provides an elegant and effective strategy to circumvent this problem. As such treatments (in the main) have already received approval for their use in humans, many of their limitations and contraindications are well known, although efficacy against new diseases must be shown in appropriate laboratory trials and clinical studies. A clear in this approach in the case of antivirals is the “relative” simplicity and a high degree of conservation of the molecular mechanisms that support viral replication—which improves the chances for a functional antiviral to inhibit replication in a related viral species. However, recent experiences have shown that while repurposing has the potential to identify such cases, great care must be taken to ensure a rigourous scientific underpinning for repurposing proposals. Here, we present a brief explanation of drug repurposing and its approaches, followed by an overview of recent viral outbreaks and associated drug development. We show how drug repurposing and combination approaches have been used in viral infectious diseases, highlighting successful cases. Special emphasis has been placed on the recent COVID-19 outbreak, and its molecular mechanisms and the role repurposing can/has play(ed) in the discovery of a treatment.
Conference papers on the topic "H3N2 virus"
1
Дешева, Юлия Андреевна, and Надежда Николаевна Петкова. "STUDY OF NEURAMINIDASE ANTIBODIES TO A(Н3N2) INFLUENZA VIRUS." In Психология. Спорт. Здравоохранение: сборник избранных статей по материалам Международной научной конференции (Санкт-Петербург, Декабрь 2021). Crossref, 2022. http://dx.doi.org/10.37539/psm300.2021.44.58.003.
Full textAbstract:
В реакции ингибирования нейраминидазной активности (РИНА) изучен коллективный иммунитет в группах пациентов различного возраста к эпидемическому вирусу гриппа A/Гонконг/4801/2014 Изучены сывороточные антитела к антигенам вируса А/H3N2 у лиц, привитых трехвалентной живой гриппозной вакциной (ЖГВ). Показано, что антитела к NA могут служить дополнительным критерием оценки иммуногенности гриппозных вакцин. In the enzyme linked lectin assay (ELLA), the collective immunity to the A/Hong Kong/4801/2014 (H3N2) influenza virus was evaluated among different age groups of patients. Serum antibodies to antigens of the A/H3N2 virus were studied in individuals vaccinated with trivalent live influenza vaccine (LAIV). It has been shown that antibodies to NA can serve as an additional criterion for assessing the immunogenicity of influenza vaccines.
2
Elbashir, Israa, Heba Al Khatib, and Hadi Yassine. "Replication Dynamics, Pathogenicity, and Evolution of Influenza Viruses in Intestinal Caco-2 Cells." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0166.
Full textAbstract:
Background: Influenza virus is a major cause of respiratory infections worldwide. Besides the common respiratory symptoms, namouras cases with gastrointestinal symptoms have been reported. Moreover, influenza virus has been detected in feces of up to 20.6 % of influenza-infected patients. Therefore, direct infection of intestinal cells with influenza virus is suspected; however, the mechanism of this infection has not been explored. AIM: To investigate influenza virus replication, cellular responses to infection, and virus evolution following serial infection in human Caucasian colon adenocarcinoma cells (Caco-2 cells). Method: Two influenza A subtypes (A/H3N2 and A/H1N1pdm 09) and one influenza B virus (B/Yamagata) were serially passaged in Caco-2. Quantitative PCR was used to study hormones and cytokines expression following infection. Deep sequencing analysis of viral genome was used to assess the virus evolution. Results: The replication capacity of the three viruses was maintained throughout 12 passages, with H3N2 virus being the fastest in adaptation. The expression of hormone and cytokines in Caco-2 cells was considerably different between the viruses and among the passages, however, a pattern of induction was observed at the late phase of infection. Deep sequencing analysis revealed a few amino acid substitutions in the HA protein of H3N2 and H1N1 viruses, mostly in the antigenic site. Moreover, virus evolution at the quasispecies level based on HA protein revealed that H3N2 and H1N1 harbored more diverse virus populations when compared to IBV, indicating their higher evolution within Caco-2 cells. Conclusion: The findings of this study indicate the possibility of influenza virus replication in intestinal cells. To further explain the gastrointestinal complications of influenza infections in-vivo experiments with different influenza viruses are needed.
3
Figueredo, Ana Lucia, Elisa Minchole, Carolina Panadero, Dinora Polanco, Clara Viñado, Sandra García, Sara Gomara, et al. "Clinical and epidemiological features in H1N1 and H3N2 influenza A virus." In Annual Congress 2015. European Respiratory Society, 2015. http://dx.doi.org/10.1183/13993003.congress-2015.pa2608.
Full text
4
Li, Su-Li, Meng-Zhe Jin, and Zhao-Hui Qi. "Evolution analysis for HA gene of human influenza A H3N2 virus (1990 – 2013)." In 2014 8th International Conference on Systems Biology (ISB). IEEE, 2014. http://dx.doi.org/10.1109/isb.2014.6990736.
Full text
5
Srinivasan, Balaji, Husein Rokadia, Steve Tung, Ronghui Wang, and Yanbin Li. "AFM Investigation of Avian Influenza Viruses." In ASME 2010 International Mechanical Engineering Congress and Exposition. ASMEDC, 2010. http://dx.doi.org/10.1115/imece2010-38952.
Full textAbstract:
The present paper describes a direct label-free diagnostic method that uses atomic force microscopy (AFM) to identify avian influenza virus strains through their electrical properties. In this method, a single virus particle is sandwiched between a rigid, conductive substrate and a conductive AFM tip (radius ∼ 8nm). Electrical characterization is achieved by probing the complex impedance spectrum of the sandwiched virus while mechanical characterization is achieved through nanoindentation. A total of three virus strains (inactivated) with different combinations of glycoprotein subtypes (H2N2, H3N5 and H4N6) were tested. Results from the electrical characterization indicate that the impedance spectra of different virus strains are indeed different. While the average electrical capacitance of a virus particle is about 17pF, the variation from one strain to another can be as high as 70%. A COMSOL Multiphysics™ simulation was carried out to estimate the electrical properties of the glycoproteins on the virus particle by comparing the simulated capacitance to the experimentally obtained values. The result indicates that the electrical conductivity of the glycoproteins is in the range of 9 to 14 mS and the dielectric constant value is around 2. The present results strongly suggest the possibility of using AFM as a diagnostic tool for direct recognition of avian influenza virus strains.